---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-010353"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:25:10.854088+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity receives Nasdaq delisting notice over independent director/audit committee non-compliance

## Summary
- Nasdaq notified Allarity on Feb 8, 2023 that it fails Listing Rules 5605(b)(1)(A) and 5605(c)(4) after director Soren G. Jensen resigned from board and audit committee, effective Feb 4, 2023.
- No immediate effect on listing; common stock continues trading under ALLR on Nasdaq Global Market.
- Cure period: must comply by earlier of next annual shareholders' meeting or Feb 4, 2024; if annual meeting before Aug 3, 2023, compliance due by Aug 3, 2023.
- Company is seeking a new independent director who qualifies for audit committee membership to regain compliance.

## SEC filing metadata
- accession: 0001213900-23-010353
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/0001213900-23-010353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/ea173153-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-010353
- JSON: https://secwatch.observer/filing/0001213900-23-010353.json
- Plain text: https://secwatch.observer/filing/0001213900-23-010353.txt

## Key facts
- Listing & Compliance Notices
  Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1)(A), 5605(c)(4)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(b)(1)(A), 5605(c)(4)
  source text: February 8, 2023, Allarity Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the resignation of Soren G. Jensen from the Company’s board and audit committee, effective on February 4, 2023, the Company no longer complies with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) which requires a majority of the board of directors to be comprised of independent directors and an audit committee of at least three independent dire
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/0001213900-23-010353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.